Based on these preclinical studies, novel BCC therapies aimed at inhibiting HH-GLI signaling have been focused on the development of SMO antagonists, such as vismodegib and sonidegib, and GLI antagonists [119]. The gene discussed is SMO; the disease is skin basal cell carcinoma.